Indivior (INDV) director buys more shares in open-market trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported an open-market purchase of common stock. On March 9, 2026, Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. After this trade, the director directly owns 5,716 shares of Indivior common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 31 shares ($1,009)
Net Buy
1 txn
Insider
Ryan Barbara
Role
Director
Bought
31 shs ($1K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 31 | $32.56 | $1K |
Holdings After Transaction:
Common Stock — 5,716 shares (Direct)
Footnotes (1)
FAQ
What insider transaction did Indivior (INDV) report for Ryan Barbara?
Indivior reported that director Ryan Barbara bought 31 shares of common stock in an open-market transaction. The purchase was recorded at a price of $32.56 per share on March 9, 2026.
What are Ryan Barbara’s total Indivior (INDV) holdings after the Form 4 trade?
Following the March 9, 2026 transaction, Ryan Barbara directly owns 5,716 shares of Indivior common stock. This total includes the 31 shares purchased in the reported open-market transaction.
Was the Indivior (INDV) insider transaction a buy or sell?
The reported Indivior insider transaction was a buy. Director Ryan Barbara executed an open-market purchase of 31 shares of common stock at $32.56 per share, increasing directly held shares to 5,716.
Did the Indivior (INDV) Form 4 include any derivative securities?
No, the reported Indivior Form 4 only shows a non-derivative transaction in common stock. There were no option exercises, warrants, or other derivative security transactions listed in this filing.